Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

Henry N. Ginsberg; Jaakko Tuomilehto; G. Kees Hovingh; Bertrand Cariou; Raul D. Santos; Alan S. Brown; Santosh K. Sanganalmath; Andrew Koren; Desmond Thompson; Frederick J. Raal

doi:10.1007/s10557-019-06852-6

Back

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

Journal article

Open access

Peer reviewed

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia

Henry N. Ginsberg, Jaakko Tuomilehto, G. Kees Hovingh, Bertrand Cariou, Raul D. Santos, Alan S. Brown, Santosh K. Sanganalmath, Andrew Koren, Desmond Thompson and Frederick J. Raal

Cardiovascular drugs and therapy, Vol.33(1), pp.69-76

01/02/2019

DOI: https://doi.org/10.1007/s10557-019-06852-6

PMCID: PMC6433806

PMID: 30734207

Abstract

Cardiovascular disease prevention

Cholesterol-lowering drugs

Clinical trials

LDL-C

PCSK9

Short Communication

Files and links (1)

url

https://doi.org/10.1007/s10557-019-06852-6View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
Creators - without role: Henry N. Ginsberg - Columbia University
Jaakko Tuomilehto - King Abdulaziz University
G. Kees Hovingh - University of Amsterdam
Bertrand Cariou - Institut du Thorax
Raul D. Santos - Hospital São Paulo
Alan S. Brown - Advocate Lutheran General Hospital
Santosh K. Sanganalmath - Regeneron
Andrew Koren - Sanofi
Desmond Thompson - Regeneron
Frederick J. Raal - University of the Witwatersrand
Publication Details: Cardiovascular drugs and therapy, Vol.33(1), pp.69-76
Publisher: Springer US
Grant note: ;
Identifiers: 9937290108331
Academic Unit: King Abdulaziz University
Language: English
Resource Type: Journal article